Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapentadol prolonged-release dose escalation versus tapentadol plus pregabalin for severe chronic low back pain with neuropathic component
NL-OMON36404Phase 3Active, not recruiting
- Sponsor
- Grünenthal GmbH
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tapentadol and pregabalin in chronic low back pain (CLBP), sponsored by Grünenthal GmbH. Primary endpoint: Change in average 3-day pain intensity score. Started Jun 2011; status: active, not recruiting.
02
Drugs
tapentadolpregabalin
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NL-OMON36404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36404.